Shares of medical device maker AngioDynamics (NASDAQ: ANGO) rose sharply today, climbing as much as 10.5% following the release of better-than-expected fiscal first-quarter 2026 results before the market opened.
AngioDynamics is a leading provider of innovative medical devices focused on minimally invasive treatments for cancer and peripheral vascular disease. Founded in 1988, the company is known for its robust product portfolio serving interventional radiology, cardiology, and surgical specialties.
For the first quarter, the company reported revenue of $75.7 million, surpassing the $72.7 million analysts had anticipated. CEO Jim Clemmer stated that the company “delivered an outstanding first quarter,” building on the strong momentum from fiscal 2025.
On profitability, however, the company remains in the red. Its adjusted loss per share of $0.10 was narrower than the estimated loss of $0.12, but still represents a loss. More notably, under Generally Accepted Accounting Principles (GAAP), the loss was significantly wider at $0.26 per share, highlighting ongoing challenges in achieving sustainable profitability.
Despite operating for 37 years, AngioDynamics has yet to reach consistent profitability. Looking ahead, management projects full-year revenue between $308 million and $313 million. It expects mid-teens growth in its med tech segment to offset flat performance in its traditional medical devices business.
Executives acknowledged that adjusted losses will continue throughout the year, forecasting a loss per share between $0.23 and $0.33. This prolonged path to profitability continues to test investor patience, with some market observers suggesting the recent stock price surge may offer a potential exit opportunity for cautious shareholders.
